drugset / Trial / NCT00438789
The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol
Summary
The primary objective is to provide access to eculizumab for PNH patient pending commercial availability.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eculizumab | Monoclonal antibody | 600 mg | Intravenous |
| Subject | Eculizumab | Monoclonal antibody | 900 mg | Intravenous |